Abstract
Prothrombin Complex Concentrates (PCC) are widely used for hemostatic indications. The relative hemostatic efficacy of each concentrate differs due to their composition. We utilized Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry to analyze the composition of these agents prior to and after activation with tissue factor.Materials and MethodBeriplex®, Cofact®, Octaplex®, Profilnine® and Prothromplex®; along with older lots of Feiba®, Konyne® and Preconativ® were obtained from various vendors. Each of these agents was activated with RecombiPlasTin® and the proteomic profile was obtained in the MW ranges of 0–150 kDa.ResultsThe native PCCs exhibited prominent peaks at 72 kDa, 67 kDa, 59 kDa, 43 kDa and 36 kDa. Upon activation the 72 kDa peak is diminished and a prominent peak is generated in all PCCs at 36–37 kDa. In the MW range of 3 kDa – 20 kDa prominent peaks at varying intensity at 13.9 kDa were noted and a minor peak at 10.5 kDa in the native PCCs. Upon activation a novel peak at 12.6 kDa is generated along with several other fragments below 9 kDa.ConclusionsDespite standardization PCCs exhibit wide compositional variations in terms of prothombin content (native) and generated thrombin. Moreover upon activation the consumption of prothrombin and the generation of thrombin also exhibit wide variations as evident by peaks at 36–37 kDa and the generation of the 12.6 kDa peak.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
